COST-EFFECTIVENESS OF THE PDSAFE HOME-BASED PERSONALIZED PHYSIOTHERAPY INTERVENTION TO PREVENT FALLS AMONG PEOPLE WITH PARKINSON’S- AN ECONOMIC EVALUATION ALONGSIDE A RANDOMISED CONTROLLED TRIAL
Author(s)
Xin Y1, Ashburn A2, Seymour KC2, Marian I3, Hulbert S2, Fitton C2, Pickering R2, Rochester L4, Roberts HC2, Nieuwboer A5, Kunkel D2, Goodwin V6, Ballinger C2, Lamb SE3, McIntosh E1
1University of Glasgow, Glasgow, UK, 2University of Southampton, Southampton, UK, 3University of Oxford, Oxford, UK, 4Newcastle University, Newcastle, UK, 5KU Leuven, Leuven, UK, 6University of Exeter, Exeter, UK
OBJECTIVES: PDSAFE is an individually-tailored, physiotherapist delivered balance, strength and strategy training programme aiming to prevent falls among people with Parkinson’s (PwP). The objective of this study was to evaluate the cost-effectiveness of PDSAFE compared with usual care for PwP who are at a higher risk of falling from a UK NHS and Personal Social Service (PSS) perspective. METHODS: RESULTS: At six months, the intervention group is associated with an incremental cost of £925 (95%CI £429.0 to £1,432.9) and a 0.007 (95%CI -0.005 to 0.019) incremental QALY, leading to an ICER of £129,514 per QALY in base case analysis. The probability that the intervention was cost-effective at the £30,000 threshold was less than 1%. Although not cost-effective in the overall population, subgroup analyses indicated that the PDSAFE intervention appears likely to be cost-effective in the participants who were cognitively severely impaired (ICER=£8,438.6/QALY gained, probability to be cost effective=57.1%), and in the participants who had moderate severity of Parkinson’s (ICER=£16,663/QALY gained, probability=53.4%). CONCLUSIONS: PDSAFE is not likely to be cost-effective for the overall Parkinson’s population however the differential effects of PDSAFE on the resource use and utility gain in subgroups of PwP indicates the importance of stratified and personalized management and recommendations for PwP.
Conference/Value in Health Info
2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan
Value in Health, Vol. 21, S2 (September 2018)
Code
PND9
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders